



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 5/06, 5/08 C07C 215/10, C11C 3/00	A1	(11) International Publication Number: WO 90/07571 (43) International Publication Date: 12 July 1990 (12.07.90)
(21) International Application Number: PCT/US89/05602 (22) International Filing Date: 14 December 1989 (14.12.89) (30) Priority data: 292,564 27 December 1988 (27.12.88) US (71) Applicant: EMORY UNIVERSITY [US/US]; Office of Sponsored Programs, 303B School of Dentistry, Atlanta, GA 30322 (US). (72) Inventors: MERRILL, Alfred, H., Jr. ; 1021 Bramwell Lane, Stone Mountain, GA 30083 (US). KINKADE, Joseph, M., Jr. ; 2384 Burnt Creek Road, Decatur, GA 30033 (US). STEVENS, Victoria, L. ; 1023 Bryant Street, Rahway, NJ 07065 (US).		(74) Agent: NEEDLE, William, H.; Needle & Rosenberg, 133 Carnegie Way, N.E., Suite 400, Atlanta, GA 30303 (US). (81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), IT (European patent), JP, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL (European patent), NO, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: METHOD OF MODIFYING CELLULAR DIFFERENTIATION AND FUNCTION AND COMPOSITIONS THEREFOR (57) Abstract A method and composition for enhancing biological response modifiers, such as promoting cellular differentiation, by using a Vitamin A or an analog thereof and sphingosine or an analog thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

METHOD OF MODIFYING CELLULAR DIFFERENTIATION
AND FUNCTION AND COMPOSITIONS THEREFOR

Technical Field

5

The present invention relates to a method of effecting the modulation of differentiation of cells by serum factors and inhibitors of Protein Kinase C. More particularly, the present invention relates to the use of sphingosine and its analogs to promote cellular differentiation.

Background Art

15

Differentiation is the modification of cells in structure or function during their course of development. Recent approaches to therapy for various types of cancer have focused on drugs that induce the maturation of the aberrant, differentiation-resistant cells causing the disease. One example of such a compound is retinoic acid, which is a less toxic analog of vitamin A. Retinoic acid has been found to be a potent inducer of differentiation in established myeloid cell lines, as well as primary cultures of cells isolated from patients with promyelocytic leukemia.

25

However, a problem exists in that certain cellular functions can be controlled by biological response modifiers only under artificial conditions. It has been found that leukemic cells are less responsive in patients than when isolated from bone marrow and cultured in nutrient-rich medium supplemented with fetal calf serum. The success of retinoic acid therapy for a leukemia patient is typically predicted by determining the ability of the compound to induce differentiation of cells isolated from bone marrow and cultured in such medium. Clinical trials and case reports indicate that retinoic acid only induces

35

differentiation in some patients and that the effectiveness of retinoic acid therapy is limited because many patients still develop infections to which they ultimately succumb. Furthermore, in many of the patients who do show
5 improvement, the retinoic acid eventually ceases to cause differentiation and the leukemic cells proliferate.

There exists a need, therefore, for an improved method of controlling cellular differentiation and function
10 using biological response modifiers.

There also exists a need for such a method which encourages differentiation under in-vivo conditions.

15 Disclosure of the Invention

Protein Kinase C is an enzyme that participates in cellular responses to many serum factors. According to the present invention, the addition of an inhibitor of
20 Protein Kinase C, such as sphingosine and its analogs, facilitates retinoic acid-induced differentiation. For example, it has been found that treating cells with both retinoic acid and sphinganine produce a more functional population of cells than those treated with retinoic acid
25 alone.

The inhibitor can therefore be useful as an adjunct in the treatment of diseases in which the progression of the disease, or in which the therapy for the
30 disease, involves growth factors, hormones, or a variety of drugs based on the mechanism of action of such compounds.

A specific example of the potential use of the present invention is the enhancement of leukemic cell
35 differentiation in response to retinoic acid. The present invention may also be used in the treatment of cancer, arthritis, atherosclerosis, diabetes, inflammatory

diseases, psoriasis, chronic granulomatous disease, and other diseases involving impaired function of cells in response to extra cellular stimuli.

5 It is an object of the present invention, therefore, to provide an improved method of controlling cellular differentiation and function using biological response modifiers.

10 It is also an object of the present invention to provide such a method which encourages differentiation under in-vivo conditions.

Brief Description of the Drawings

15

Fig. 1 summarizes the uptake of [³H] retinoic acid by HL-60 cells;

20 Fig. 2 summarizes the effect of sphinganine on retinoic acid-induced differentiation of HL-60 cells; and

Fig. 3 illustrates the respiratory burst of differentiated HL-60 cells.

25 Best Mode of Carrying Out the Invention

The present invention relates to the use of an inhibitor of Protein Kinase C, such as sphingosine and its analogs, to enhance cell differentiation in response to
30 other agents.

The effects of different sera on RA-induced differentiation are shown in Fig. 1. The cells grown in serum-free medium show the most morphological (only 10%
35 remained promyelocytic) as well as functional (82% were NBT+) maturation after 4 days in RA. Serum has an inhibitory effect on differentiation by both criteria and

varied with the source. FCS allows the most differentiation (25% remained promyelocytic and 58% were NBT+) while maturation in calf serum (HyClone, 43% were promyelocytic and 43% NBT+), and human serum (44% were promyelocytic and 37% NBT+), was less. As is typically seen, a small percentage of the cells in each sera group exhibit a more differentiated phenotype without addition of RA.

10 It has been found that different retinoic acid-induced differentiation can be effected by sera. The effects of different sera on retinoic acid-induced differentiation of HL-60 cells are shown in Table I, below. HL-60 cells were originally isolated from a patient with
15 acute myelocytic leukemia and can be induced to differentiate into either monocyte/macrophage-like cells upon treatment with phorbol esters or $1\alpha,25$ -dihydroxyvitamine D_3 or granulocytes when placed in media containing retinoic acid.

20

HL-60 cells (between passages 20 and 30) were adapted to growth in the RPMI 1640 medium supplemented with no serum, fetal calf serum, human serum [type AB from male donors (Sigma)], or calf serum (all at 10% final
25 concentration) and maintained by subculturing every 3 or 4 days at a density of 2.5×10^5 cells/ml. Differentiation was assessed after 4 of days growth in either the presence or absence of 1 μ M RA (added from a 10 mM stock solution in DMSO to an initial cell number of 2.5×10^5 cells/ml) by
30 morphology and nitro blue tetrazolium (NBT) reduction. Differentiation in response to retinoic and treatment was assessed by morphology (the percentage of the cellular population in the various stages of granulocytic differentiation) as well as functional assays (the activity
35 of the NADPH oxidase as measured by the reduction of nitro blue tetrazolium (NBT) when activated by phorbol esters. Morphology was judged on slides prepared with a Shandon

Southern cytospin stained with Wright-Giemsa stain (Camco Quik II). The results from a representative determination are also shown in Table I.

5 These findings have been confirmed by repeating the measurements twice for cells in serum-free medium and at least four times for those in serum-containing media. In each case, 200 cells were scored. The percentage of cells capable of reducing NBT was determined by counting
10 the number which contained precipitated formazan after a 30 minute, 37°C incubation with an equal volume of NBT (1 mg/ml in 140 mM NaCl, 9.2 mM Na₂HPO₄, 1.3 mM NaH₂PO₄, pH 7.4) and 160 nM phorbol 12-myristate 13-acetate. The percentages shown represent the average of three
15 determinations in which at least 200 cells were counted. In Table I, Blast=myeloblast, Pro=promyelocyte, Myelo=myelocyte, Meta=meta=myelocyte, Band=banded neutrophil, and Seg=segmented neutrophil.

20 The results were as follows:

TABLE I

	<u>Serum</u>	<u>[RA]</u>	<u>Blast</u>	<u>Pro</u>	<u>Myelo</u>	<u>Meta</u>	<u>Band</u>	<u>Seg</u>	<u>NBT+</u>
	None	—	0	86	10	4	0	0	17%
25		1 uM	0	10	33	33	14	10	82%
	FCS	—	0	88	6	2	1	3	7%
		1 uM	0	25	33	25	9	8	58%
30	Calf	—	0	87	11	1	1	0	6%
		1 uM	1	43	31	17	8	8	43%
	Human	—	0	84	11	3	1	1	7%
35		1 uM	0	44	35	18	2	1	37%

It was found, therefore, that cells grown in serum-free medium showed the most morphological and functional maturation after 4 days in retinoic acid. Serum

had an inhibitory effect on differentiation by both criteria, and differentiation varied with the source. Fetal calf serum allowed the most differentiation while maturation in calf serum and human serum was less.

5

It has been determined that the enzyme Protein Kinase C plays an important role on the serum effects on retinoic acid-induced differentiation. It has also been found that sphinganine enhances retinoic acid-induced differentiation. Sphinganine, or 2D- or D-erythro-2- or (2S,3R)-2 amino, 1,3-octadecanediol, is a constituent of the sphingolipids and is known to be a potent inhibitor of Protein Kinase C. To determine the effects of sphinganine on retinoic acid-induced differentiation of HL-60 cells, 5 x 10⁵ cells plated in 2 ml of RPMI 1640 medium containing the indicated serum (10%) in 12-well culture dishes (Costar) were treated with sphinganine (prepared as the 1:1 molar complex with bovine serum albumin as previously described) alone or in combination with 1 μ M RA. The sphinganine was added daily to give the following final concentrations: serum-free, 1.0 μ M/day; FCS, 2.5 μ M/day; calf serum, 4.0 μ M/day; human serum, 4.0 μ M/day. The degree of maturity of each group was assessed by morphology (open bars, expressed as the percentage of cells which had matured beyond the promyelocyte stage) and NBT reduction (solid bars, determined as described above). The results for the serum-containing groups, reported as averages of at least 4 experiments shown \pm S.E., are summarized in Fig. 2.

In Fig. 2, C=control, RA=retinoic acid alone, and
+Sa=retinoic acid plus sphinganine.

It was found that sphinganine had little effect
5 on the retinoic acid-induced differentiation of HL-60 cells
in serum-free medium; however, it increased the percentage
of mature cells in all serum-containing media. The cells
in fetal calf serum treated with retinoic acid and
sphinganine differentiated to levels close to those seen
10 with retinoic acid alone in serum-free medium (as judged by
morphology). Likewise, the percentage of mature cells
after retinoic acid and sphinganine treatment in calf serum
was similar to those obtained with retinoic acid in FCS.
The percentage of NBT positive cells was also increased
15 although to a lesser extent. Treatment with sphinganine
alone (i.e., without retinoic acid) also slightly increased
the percentage of differentiated cells.

It has also been found that the initial rate of
20 superoxide production in response to the chemotactic
peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine
(fMLP) can be increased with retinoic acid alone relative
to undifferentiated cells. It was further found that the
rate of fMLP-initiated respiratory burst was further
25 increased by treatment with both retinoic acid and
sphinganine.

During granulocytic maturation, cells normally acquire the ability to produce superoxide when activated by physiological stimuli such as the chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) and
5 phorbol 12-myristate 13-acetate (PMA). Whereas phorbol ester-stimulated superoxide production requires only a functional NADPH oxidase, the response to fMLP entails the presence of the fMLP receptor and the coupling mechanisms to the oxidase. HL-60 cells induced to differentiate by
10 dimethylsulfoxide and dimethylformamide appear to develop all these components and produce superoxide when stimulated by fMLP, as reported by Skubitz et al., Blood 59,586 (1982) and Brandt et al. Cancer Res. 41,4947 (1981). However, cells treated with retinoic acid show little activation in
15 response to this peptide, suggesting that maturation induced by this agent is incomplete. To determine whether sphinganine treatment affects the ability of retinoic acid-differentiated HL-60 cells to be activated by fMLP, the rate of superoxide production in response to both this
20 peptide and PMA was quantitated.

Cells were grown in RPMI 1640 medium supplemented with 10% calf serum with no additions (control), 1 uM retinoic acid, 4.0 uM sphinganine (Sa, added on days 1 and
25 2 only), or both 1 uM retinoic acid and 4.0 uM sphinganine (added on days 1 and 2). After 4 days, the cells were collected by centrifugation and washed with phosphate

buffered saline (PBS, 0.1 g/l CaCl_2 , 0.2 g/l KCl , 0.2 g/l KH_2PO_4 , 0.1 g/l $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 8.0 g/l NaCl , and 2.16 g/l $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$) containing glucose (1 g/l). The cells were then resuspended in PBS + glucose at a density of 1×10^7 cells/ml. The respiratory burst of each group was quantitated by measuring the reduction of cytochrome c (25 mg/ml) as reflected by the change in absorbance at 549 nm minus 540 nm measured with a SLM Aminco DW-2000 spectrophotometer in the dual wavelength mode. Each measurement was done with 2.4×10^6 cells in a total volume of 2.4 ml. The respiratory burst shown in the top panel of Fig. 3 was initiated by fMLP (1 μM) while that in the lower panel was initiated with PMA (100 nM).

As summarized in Fig. 3, the response to fMLP in cells treated with retinoic acid alone increased by 220% relative to the undifferentiated cells, and the rate of respiratory burst was increased by 410% in HL-60 cells treated with both retinoic acid and sphinganine relative to the control. Some variability in the fMLP-stimulated rate of superoxide production was seen between different groups of cells: averages of results from 5 separate experiments show that this rate increased $75 \pm 30\%$ for retinoic acid alone and $299 \pm 100\%$ for retinoic acid plus sphinganine.

25

The rate of superoxide production in response to PMA was increased in cells differentiated with retinoic acid by 210% and with retinoic acid plus sphinganine by

230% both relative to the control rate in amounts consistent with the increases in NBT reduction above. The average increase, calculated from five experiments, was $82 \pm 24\%$ for retinoic acid treated cells and
5 $123 \pm 60\%$ for cells treated with both retinoic acid and sphinganine. Therefore, because the increase in superoxide production when retinoic acid and sphinganine are used together is greater when stimulated by fMLP than by PMA, it appears that the long-chain base aids the HL-60 cells to
10 differentiate more completely so that they become responsive to physiological agonists.

It has been found, therefore, that serum influences the ability of retinoic acid to induce cellular
15 differentiation. Also, the addition of sphinganine has been found to not only increase the percentage of cellular population when differentiated, but also promotes more functional maturation of the cells. The use of sphingosine and its analogs as enhancers of biological response
20 modifiers provides means for overcoming the frequent failures of retinoic acid therapy, and provides differentiation under in-vivo conditions.

Furthermore, the present invention is not limited
25 to retinoic acid, but applies to all systems with key processes that are inhibited by sphingosine and its analog and are involved in a biological process of interest.

11

For example, a daily intervenous dosage of approximately 50 mg and up to 0.5 mg may be used, which compares to clinical studies of 13-cis-retinoic acid where doses of 50 to 100 mg per day are used.

5

WHAT IS CLAIMED IS:

1. A method of promoting cellular differentiation, comprising the step of treating said cells with an effective amount of sphingosine or an analog thereof.
5
2. The method of Claim 1, wherein said cellular differentiation is induced by Vitamin A or an analog thereof.
10
3. The method of Claim 1, wherein said analog of sphingosine is sphinganine.
4. The method of claim 1, wherein said cellular differentiation is retinoic acid-induced differentiation.
15
5. The method of claim 1, wherein said cells are leukemic cells.
- 20 6. The method of claim 1, wherein said cells are HL-60 cells.
7. A method of promoting cellular differentiation in a serum-containing environment, comprising the step of treating cells with effective amounts of a biological response modifier and sphingosine or an analog thereof.
25

8. The method of Claim 7, wherein said biological response modifier is Vitamin A or an analog thereof.

9. The method of Claim 7, wherein said biological
5 response modifier is retinoic acid.

10. The method of Claim 7, wherein said analog of sphingosine is sphinganine.

10 11. The method of claim 7, wherein said environment is in-vivo.

12. The method of claim 7, wherein said environment is a serum-containing media.

15

13. The method of claim 12, wherein said media contains fetal calf serum.

14. The method of claim 12, wherein said media
20 contains human serum.

15. A method of increasing superoxide production by cells, comprising the step of treating said cells with effective amounts of Vitamin A or an analog thereof and
25 sphingosine or an analog thereof.

16 The method of Claim 15, wherein said analog of Vitamin A is retinoic acid.

17. The method of Claim 15, wherein said analog of sphingosine is sphinganine.

5 18. The method of claim 15, wherein said superoxide production is in response to a chemotactic peptide.

19. The method of claim 18, wherein said chemotactic peptide is N-formyl-L-methionyl-L-leucyl-L-phenylalanine.

10

20. A compound for promoting cellular differentiation, comprising effective amounts of Vitamin A or an analog thereof and sphingosine or an analog thereof.

15 21. The compound of Claim 20, wherein said analog of Vitamin A is retinoic acid.

22. The compound of Claim 20, wherein said analog of sphingosine is sphinganine.

20

23. A compound for enhancing retinoic acid-induced cellular differentiation, comprising an effective amount of sphingosine or an analog thereof.

25 24. The compound of Claim 23, wherein said analog of sphingosine is sphinganine.

15


25. A compound for enhancing a biological response modifier, and sphingosine or an analog thereof.

26. The compound of Claim 25, wherein said analog of
5 Vitamin A is retinoic acid.


27. The compound of Claim 25, wherein said analog of sphingosine is sphinganine.


10

1 / 3

**FIG 1**

2 / 3

**FIG 2**

**FIG 3**

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US89/05602**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC
IPC(5): C12N 5/06, 5/08; C07C 215/10; C11C 3/00
U.S. Cl.: 435/240.1, 240.2; 260/405.5; 564/504

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System

Classification Symbols

U.S. Cl.

435/240.1, 240.2; 514/559; 514/725; 260/405.5;
 564/507; 514/885

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched ⁸

Databases: Chemical Abstracts Services Online: File CA 1967-1990;
 File Biosis, 1969-1990. See attachment for search terms.

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
<u>X</u> <u>Y</u>	The FASEB journal, Volume 2, issued 25 march 1988, Stevens et al, "Protein Kinase C Involvement in HL-60 differentiation probed by long-chain (Sphingoid) Bases." Abstract #7702. See entire abstract	1-6, 15-27 7-14
X	Journal of Biological Chemistry, Volume 261, Issued 25 September 1986, Merrill et al, "Inhibition of Phorbol Esterdependent Differentiation of Human Promyelocytic Leukemic (HL-60) Cells by Sphinganine and Other Long-Chain Bases," pages 12610-12615. See entire article.	23-25,27
A	Blood, Volume 62, issued October 1983, Koeffler, "Induction of Differentiation of Human Acute Myelogenous Leukemia Cells: Therapeutic Implications," pages 709-721. See especially pages 715-716.	1-27

* Special categories of cited documents: ¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

16 MARCH 1990

09 APR 1990

International Searching Authority

Signature of Authorized Officer

TSA/IIS

GAIL E. POULOS

ATTACHMENT TO FORM PCT/ISA/210, PART II.

SEARCH TERMS

Sphingosine
Sphinganine
Vitamin A
Retinoic Acid
All Differentiation

DOCKET NO: RWS-80019
SERIAL NO: 09/936, 3/6
APPLICANT: Streekstra et al.
LERNER AND GREENBERG P.A.
P.O. BOX 2480
HOLLYWOOD, FLORIDA 33022
TEL. (954) 925-1100